You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
- 2. The interplay between DNA damage response and mitochondrial dysfunction in radiotherapy
- 3. Summit's dual-acting drug scores lung cancer win
- 4. ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease
- 5. Personalised breast cancer therapy: A new treatment approach for patients with limited tamoxifen efficacy
- 6. After cancer: Study explores caring-healing modalities for survivors
- 7. How cutting lipids could starve breast cancer
- 8. Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
- 9. A multifunctional MRI model based on IVIM and DKI predicts HIF-1α, Ki-67, and VEGF status in breast carcinoma
- 10. Ridgeline Construction Partners with Stacy Wolfe Breast Cancer Foundation, Donates $250 Per Roof Replacement
Last updated at 22:11 GMT
Hot News Makers
Health/Pharma Companies
-
43695.77
-
4117.45
-
1884.94
-
1196.21
-
744.13
-
661.73
-
528.12
-
520.53
-
496.09
-
404.41
Drugs, Treatments, Trials
-
11729.15
-
1813.50
-
1410.50
-
976.50
-
797.81
-
634.72
-
373.66
-
347.57
-
253.10
-
247.19
Last updated at 10:10 GMT
